Clinical Trial

Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC

Study acronym: TOWARDS-II
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a prospective phase 2 study to use Functional Precision Oncology (FPO) to predict, prevent and treat early metastatic recurrence in subjects with HR-low/Her2 negative or triple negative breast cancer.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2022-07-18; most recent amendment 2026-02-18.
Status change: Suspended → Recruiting 2023-05-05
Status change: Not Yet Recruiting → Suspended 2023-01-06
Trial Details
NCT Number NCT05464082
Lead Sponsor University of Utah
Collaborators: United States Department of Defense
Conditions Breast Cancer Recurrent
Enrollment 80 participants
Start Date 2023-01-06
Primary Completion 2026-09-30 (estimated)
Study Completion 2028-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-20